Gynecomastia is a well-recognized effect of oral and also parenteral estrogen therapy. The reported incidence (and severity) of this event varies from 40% to 77%. [19,20,35] In our study ...

Increasingly, injectable manufacturers recognise that to achieve maximum profitability, they need to focus on the value they ...

Parenteral estrogen therapy has the advantage of giving protection against the effects of andropause (similar to the female menopause), which are induced by conventional androgen suppression and ...

as well as its Intravenous Choline Chloride therapy for patients requiring parenteral support. In the recent earnings report, Protara Therapeutics revealed key financial highlights for the quarter ...

On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect to report interim ...

Q3 2024 Earnings Call Transcript November 7, 2024 Ironwood Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

In a rare and complex case, a baby born highly premature at just 27 weeks gestation has successfully overcome severe life-threatening conditions after receiving specialized care at Narayana Health ...

The 10.3% of participants that experienced recrudescence -- recurrent malaria caused by the same strain of P. falciparum as ...

This study found artemisinin partial resistance in Ugandan children with complicated malaria associated with the Pfkelch13 A675V variation and also found suboptimal 28-day efficacy of parenteral ...

Etiology and Treatment Advances of Hematochezia in Infants Aged ≤3 Months. Journal of Biosciences and Medicines, 12, 273-285. doi: 10.4236/jbm.2024.1211023 . Acute intussusception is most prevalent in ...

Corstasis to present pivotal trial data on Bumetanide Nasal Spray at AHA 2024, highlighting safety, and efficacy. #AHA2024.